R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years : Results of a randomized phase 2 study from the Spanish GELTAMO group
| Autor: | Ana Batlle-López, Esther González-García, Francisco-Javier Peñalver, Jose Angel Hernandez-Rivas, Ruben Fernández-Álvarez, Mariana Bastos, Miguel A Fuertes, Norma C. Gutiérrez, José-María Moraleda, Carlos Grande, Alejandro Martín, Francisco Gual-Capllonch, José-María Guinea, Eva González-Barca, Olga García, Marc Sorigue, María-Jesús Peñarrubia, Eva Gimeno, Juan-Manuel Sancho |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Cancer Research Limfomes Phases of clinical research Gastroenterology Ventricular Function Left 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Clinical endpoint Prospective Studies Prospective cohort study Original Research Aged 80 and over Ejection fraction N-terminal pro-B-type natriuretic peptide biology N‐terminal pro‐B‐type natriuretic peptide Diffuse large B-cell lymphoma Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Troponin Liposomal doxorubicin Treatment Outcome Oncology Vincristine 030220 oncology & carcinogenesis Female Lymphomas Lymphoma Large B-Cell Diffuse Rituximab medicine.medical_specialty Cèl·lules B lcsh:RC254-282 03 medical and health sciences Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Adverse effect Cyclophosphamide Aged Retrospective Studies Cardiotoxicity B cells business.industry diffuse large B‐cell lymphoma Clinical Cancer Research medicine.disease 030104 developmental biology Doxorubicin N-terminal pro-B-type biology.protein Prednisone business Natriuretic peptide |
| Zdroj: | Cancer Medicine Zaguán. Repositorio Digital de la Universidad de Zaragoza instname Zaguán: Repositorio Digital de la Universidad de Zaragoza Universidad de Zaragoza Cancer Medicine, Vol 10, Iss 4, Pp 1314-1326 (2021) Dipòsit Digital de la UB Universidad de Barcelona |
| Popis: | The use of non‐pegylated liposomal doxorubicin (Myocet®) in diffuse large B‐cell lymphoma (DLBCL) has been investigated in retrospective and single‐arm prospective studies. This was a prospective phase 2 trial of DLBCL patients ≥60 years old with left ventricular ejection fraction (LVEF) ≥55% randomized to standard R‐CHOP or investigational R‐COMP (with Myocet® instead of conventional doxorubicin). The primary end point was to evaluate the differences in subclinical cardiotoxicity, defined as decrease in LVEF to The use of non‐pegylated liposomal doxorubicin (Myocet®) in diffuse large B‐cell lymphoma (DLBCL) has been investigated in retrospective and single‐arm prospective studies. This prospective randomized phase 2 trial of RCOMP versus RCHOP in DLBCL patients ≥60 years and normal cardiac function demonstrated that R‐COMP is a feasible immunochemotherapy schedule for DLBCL patients ≥60 years, with similar efficacy to R‐CHOP. However, the use of non‐pegylated doxorubicin instead of conventional doxorubicin was not associated with less early cardiotoxicity, although some reduced cardiac safety signals were observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|